跳至主要内容
临床试验/NCT07228312
NCT07228312招募中不适用

A Multicenter, Prospective, Single-Arm Observational Study to Evaluate the Safety and Effectiveness of the Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

Johnson & Johnson Medical (Shanghai) Ltd.8 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2026年1月28日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
8
主要终点
Percentage of Participants with Modified Rankin Scale (mRS) Score of 0-2 at 12 Months Post-Procedure

研究概览

简要总结

The purpose of this study is to assess how safe choydar flow-directed mesh stent is and how well it works in the treatment of unruptured intracranial aneurysms (a condition in which a bulging blood vessel in the brain can burst and cause bleeding) in a real-world setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Participants meeting all the following inclusion criteria will be included:
  • •Preoperative inclusion criteria:
  • •Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA) prior to surgery, wide-neck (neck width greater than or equal to [>=] 4 millimeters [mm] or dome-to-neck ratio less than [<] 2) saccular or fusiform aneurysms, and the parent artery diameter must be >= 2.0 mm and less than or equal to [<=] 6.0 mm
  • •Participants and/or their authorized representatives understand the purpose of the study, and are willing to voluntarily participate in the study and sign the informed consent form (ICF)
  • •Prior to enrollment, a clinical decision has already been made to use the choydar flow-directed mesh stent
  • •Participants who are willing and able to return for all follow-up visits as required by the study protocol
  • •Intraoperative inclusion criteria:
  • •- Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by DSA during the procedure, wide-neck (neck width >= 4 mm or dome-to-neck ratio <2) saccular or fusiform aneurysms, and the parent artery diameter must be >= 2.0 mm and <= 6.0 mm

排除标准

  • •Participants meeting any of the following exclusion criteria will be excluded:
  • •Participants with anatomy are unsuitable for flow diverter passage or placement or lesions unsuitable for flow diverter delivery and deployment (for example, the lesion vessel is excessively tortuous or tiny, the flow diverter cannot reach the lesion site, stenosis exists in the target vessel of recurrent aneurysm, or the flow diverter is not completely deployed)
  • •Participants who are allergic to contrast media
  • •Participants who are allergic to nickel-titanium alloy or platinum-tungsten alloy
  • •Participants who are contraindicated for antiplatelet and/or anticoagulant therapy
  • •Participants with active bacterial infections
  • •Participants who are confirmed positive pregnancy (for example, via test or oral communication) according to the site-specific standard of care
  • •Participants who are currently participating in an investigational (drug, device, etc.) clinical study that may confound the study endpoints (excluding observational, natural history, and/or epidemiological studies that do not require interventions)

研究组 & 干预措施

Choydar Flow-Directed Mesh Stent

The choydar flow-directed mesh stent will be used in accordance to its Instructions For Use (IFU) in participants with unruptured intracranial aneurysms. Participants will not receive any other intervention as a part of this study.

结局指标

主要结局

Percentage of Participants with Modified Rankin Scale (mRS) Score of 0-2 at 12 Months Post-Procedure

时间窗: At 12 months follow-up post-procedure

Percentage of participants with mRS score of 0-2 at 12 months post-procedure will be reported. The mRS score is issued to evaluate the improvement of neurological function. It assesses the ability of participants with neurological disease to live independently. There are 7 levels of this score, 0 points represent no symptoms of disability, higher scores mean worse prognosis of participants , and 6 points represent death.

Complete Aneurysm Occlusion Rate at 12 Months Post-Procedure (Raymond-Roy Class I)

时间窗: At 12 months follow-up post-procedure

Complete aneurysm occlusion rate as per Raymond Roy classification criteria (Class I) is defined as complete obliteration (no contrast filling in aneurysm body or neck). It is calculated as follows: number of target aneurysms achieving Raymond-Roy Class I occlusion at 12-month follow-up post-procedure/number of target aneurysms with 12-month imaging evaluation \* 100 percent (%).

Adequate Aneurysm Occlusion Rate at 12-month Follow-up Post-Procedure (Raymond-Roy Classes I and II)

时间窗: At 12 months follow-up post-procedure

Adequate aneurysm occlusion rate as per Raymond Roy classification criteria (Class II and III) is defined as Class II: residual neck (contrast filling in aneurysm neck but none in aneurysm body) and Class III: residual aneurysm (contrast filling in aneurysm body). It is calculated as follows: number of target aneurysms achieving Raymond-Roy Class I/II occlusion at 12-month follow-up post-procedure/number of target aneurysms with 12-month imaging evaluation \* 100 %.

Percentage of Participants with Immediate Technical Success Rate of Procedure

时间窗: At Day 0 (Day of procedure)

Percentage of participants with immediate technical success rate of procedure will be reported. Immediate technical success of the procedure is defined as the percentage of participants in whom the flow diverter is successfully deployed during the procedure, with accurate positioning confirmed by intra-procedure angiography, and with effective coverage of the aneurysm neck by the implant. It is calculated as follows: number of participants with successful placement of the investigational device/total number of participants undergoing the treatment \* 100 %.

Re-treatment Rate of Target Aneurysm at 12-Month Follow-up Post-Procedure

时间窗: At 12 months follow-up post-procedure

The incidence of re-treatment of the target aneurysm at 12 months follow-up post-procedure will be reported.

Number of Participants with Major Ischemic/Hemorrhagic Events and/or Death During Perioperative Period

时间窗: Perioperative

Number of participants with major ischemic/hemorrhagic events and/or death during perioperative period will be reported. Major ischemic/hemorrhagic events are defined as an increase of \>= 4 points in the National Institutes of Health Stroke Scale (NIHSS) score compared with the previous score.

Number of Participants with Major Ischemic/Hemorrhagic Events and/or Death During 12-Month Follow-up

时间窗: At 12 months follow-up post-procedure

Number of participants with major ischemic/hemorrhagic events and/or death during 12 months follow-up period will be reported. Major ischemic/hemorrhagic events are defined as an increase of \>= 4 points in the NIHSS score compared with the previous score.

Rupture Rate of Target Aneurysm During 12-Month Follow-Up Post-Procedure

时间窗: At 12 months follow-up post-procedure

The incidence of rupture of the target aneurysm within 12 months post-procedure will be reported.

Number of Participants with Severe in-Stent Stenosis (Greater Than [>] 50%) During 12-Month Follow-up

时间窗: At 12 months follow-up post-procedure

Number of participants with severe in-stent stenosis during 12-month follow-up period will be reported. The percent stenosis is calculated according to the calculation method of Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) study as follows: (1 - Ds \[Diameter of the artery at the site of the most severe stenosis\]/Dn \[Diameter of the normal artery\]) \* 100%.

次要结局

未报告次要终点

研究者

发起方
Johnson & Johnson Medical (Shanghai) Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

A Study of Choydar Flow-Directed Mesh Stent in the... | 临床试验